IMIDAZOTETRAZINE COMPOUNDS
New synthetic methods to provide access to previously unexplored functionality at the C8 position of imidazotetrazines. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 hours), a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent was derived. Promising compounds were identified that possess activity against a panel of GBM cell lines, appropriate hydrolytic and metabolic stability, and brain-to-serum ratios dramatically elevated relative to TMZ, leading to lower hematological toxicity profiles and superior activity to TMZ in a mouse model of GBM..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Europäisches Patentamt - (2020) vom: 13. Feb. Zur Gesamtaufnahme - year:2020 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
HERGENROTHER PAUL J [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-02-13, Last update posted on www.tib.eu: 2023-08-16, Last updated: 2023-08-18 |
---|
Patentnummer: |
WO2020033880 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA009122923 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA009122923 | ||
003 | DE-627 | ||
005 | 20230818084646.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210531s2020 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA009122923 | ||
035 | |a (EPA)WO2020033880 | ||
035 | |a (EPA)69415152 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a HERGENROTHER PAUL J |e verfasserin |4 aut | |
245 | 1 | 0 | |a IMIDAZOTETRAZINE COMPOUNDS |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2020-02-13, Last update posted on www.tib.eu: 2023-08-16, Last updated: 2023-08-18 | ||
520 | |a New synthetic methods to provide access to previously unexplored functionality at the C8 position of imidazotetrazines. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 hours), a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent was derived. Promising compounds were identified that possess activity against a panel of GBM cell lines, appropriate hydrolytic and metabolic stability, and brain-to-serum ratios dramatically elevated relative to TMZ, leading to lower hematological toxicity profiles and superior activity to TMZ in a mouse model of GBM. | ||
650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
650 | 4 | |a che | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a 615 | |
700 | 0 | |a FAN TIMOTHY M |4 aut | |
700 | 0 | |a SVEC RILEY L |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 13. Feb. |
773 | 1 | 8 | |g year:2020 |g day:13 |g month:02 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/69415152/publication/WO2020033880A1?q=WO2020033880 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2020 |b 13 |c 02 |
951 | |a AR | ||
952 | |j 2020 |b 13 |c 02 |